(Q35563953)

8 August 2017

1 reference

title

Yin and Yang: complement activation and regulation in Alzheimer's disease (English)

1 reference

8 August 2017

Yin and Yang: complement activation and regulation in Alzheimer’s disease (English)

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

23 March 2024

main subject

Alzheimer's disease

0 references

complement activation

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14568360

23 March 2024

author name string

Yong Shen

1

1 reference

8 August 2017

Seppo Meri

2

1 reference

8 August 2017

language of work or name

1 reference

1 August 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0301008203001308?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

https://api.elsevier.com/content/article/PII:S0301008203001308?httpAccept=text/plain

23 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

23 March 2024

published in

Progress in Neurobiology

1 reference

8 August 2017

volume

70

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

463-472

1 reference

Localization and cell association of C1q in Alzheimer's disease brain

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Role of the beta-amyloid precursor protein in Alzheimer's disease.

23 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

23 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

23 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

The frequency of C4B variants of complement in familial and sporadic Alzheimer disease

23 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed

23 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies

23 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice

23 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide

23 March 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia.

23 March 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.

23 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins

23 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor

23 March 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

A postulated mechanism for heparin's potentiation of C1 inhibitor function

23 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Efficiency of fucans in protecting porcine endothelial cells against complement activation and lysis by human serum

23 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells

23 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

23 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction

23 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

23 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Structural studies on fucoidans from the brown seaweed Sargassum stenophyllum

23 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study.

23 March 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Inflammatory mechanisms in Alzheimer's disease.

23 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia

23 March 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease

23 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells.

23 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

The chemotactic receptor for human C5a anaphylatoxin

23 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein

23 March 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Alzheimer disease's double-edged vaccine

23 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution.

23 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells

23 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

23 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

23 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning

23 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Anticomplementary activity of boswellic acids--an inhibitor of C3-convertase of the classical complement pathway

23 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Immunopotentiating compounds from Tinospora cordifolia

23 March 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Targeting complement in therapy

23 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

C1-inhibitor: an anti-inflammatory reagent with therapeutic potential

23 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Induction of complement C9 messenger RNAs in human neuronal cells by inflammatory stimuli: relevance to neurodegenerative disorders

23 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium

23 March 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema

23 March 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Amyloid plaque core protein in Alzheimer disease and Down syndrome

23 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

23 March 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Is there a future for vaccination as a treatment for Alzheimer's disease?

23 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Activation of the classical complement pathway in brain tissue of Alzheimer patients

23 March 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain

23 March 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

23 March 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

23 March 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement regulatory molecules: application to therapy and transplantation.

23 March 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

23 March 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3.

23 March 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Molecular organization and function of the complement system

23 March 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

HLA-linked complement markers in Alzheimer's and Parkinson's disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer type

23 March 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

23 March 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Neuronal expression of a functional receptor for the C5a complement activation fragment

23 March 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

The proteolytic activation systems of complement

23 March 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

23 March 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

A fucan from the brown seaweed Spatoglossum schröederi inhibits Chinese hamster ovary cell adhesion to several extracellular matrix proteins

23 March 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement activation by beta-amyloid in Alzheimer disease

23 March 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Clinical trial of indomethacin in Alzheimer's disease.

23 March 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity

23 March 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

23 March 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

The role of APP processing and trafficking pathways in the formation of amyloid beta-protein

23 March 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement-mediated neurotoxicity is regulated by homologous restriction.

23 March 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain.

23 March 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide

23 March 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement activation by neurofibrillary tangles in Alzheimer's disease.

23 March 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

A safer vaccine for Alzheimer's disease?

23 March 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease

23 March 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis

23 March 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

A role for the beta-amyloid precursor protein in memory?

23 March 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.

23 March 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Expression of Receptors for Complement Anaphylatoxins C3a and C5a Following Permanent Focal Cerebral Ischemia in the Mouse

23 March 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Peripheral nerve CR1 express in situ cofactor activity for degradation of C3b

23 March 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Erythrocyte C3b/C4b receptors (CR1) in patients with myasthenia gravis

23 March 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement C1-inhibitor expression in Alzheimer's disease

23 March 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis

23 March 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement gene expression in human brain: comparison between normal and Alzheimer disease cases

23 March 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease

23 March 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q.

23 March 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation.

23 March 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

23 March 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q.

23 March 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin

23 March 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Inflammation and therapeutic vaccination in CNS diseases

23 March 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis

23 March 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.

23 March 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice

23 March 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease

23 March 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding

23 March 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.PNEUROBIO.2003.08.001

23 March 2024

Identifiers

1 reference

8 August 2017

1 reference